6848 Stock Overview
Researches, develops, manufactures, and sells reagents and devices for life science and molecular diagnosis in Europe, the United States, Asia, Taiwan, Africa, and Australia. More details
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 0/6 |
Past Performance | 2/6 |
Financial Health | 2/6 |
Dividends | 4/6 |
My Notes
Capture your thoughts, links and company narrative
RBC Bioscience Corporation Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | NT$18.20 |
52 Week High | NT$24.60 |
52 Week Low | NT$14.70 |
Beta | 0.068 |
1 Month Change | -8.77% |
3 Month Change | -7.61% |
1 Year Change | 12.00% |
3 Year Change | -45.52% |
5 Year Change | n/a |
Change since IPO | -62.65% |
Recent News & Updates
Recent updates
Shareholder Returns
6848 | TW Life Sciences | TW Market | |
---|---|---|---|
7D | 2.2% | -2.2% | 0.9% |
1Y | 12.0% | -24.2% | 28.9% |
Return vs Industry: 6848 exceeded the TW Life Sciences industry which returned -23.8% over the past year.
Return vs Market: 6848 underperformed the TW Market which returned 28.5% over the past year.
Price Volatility
6848 volatility | |
---|---|
6848 Average Weekly Movement | 5.7% |
Life Sciences Industry Average Movement | 4.2% |
Market Average Movement | 4.5% |
10% most volatile stocks in TW Market | 7.8% |
10% least volatile stocks in TW Market | 2.1% |
Stable Share Price: 6848 has not had significant price volatility in the past 3 months compared to the TW market.
Volatility Over Time: 6848's weekly volatility (6%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1995 | n/a | n/a | www.rbcbioscience.com |
RBC Bioscience Corporation researches, develops, manufactures, and sells reagents and devices for life science and molecular diagnosis in Europe, the United States, Asia, Taiwan, Africa, and Australia. It offers molecular biomedical diagnostic and research reagents, gene extraction automatic testing instruments, and gene extraction reagent tissues; automated nucleic acid extractors; and nucleic acid extraction kits. The company sells its products through distributors.
RBC Bioscience Corporation Fundamentals Summary
6848 fundamental statistics | |
---|---|
Market cap | NT$236.16m |
Earnings (TTM) | NT$17.27m |
Revenue (TTM) | NT$194.62m |
13.7x
P/E Ratio1.2x
P/S RatioIs 6848 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
6848 income statement (TTM) | |
---|---|
Revenue | NT$194.62m |
Cost of Revenue | NT$106.26m |
Gross Profit | NT$88.36m |
Other Expenses | NT$71.09m |
Earnings | NT$17.27m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 1.33 |
Gross Margin | 45.40% |
Net Profit Margin | 8.87% |
Debt/Equity Ratio | 185.5% |
How did 6848 perform over the long term?
See historical performance and comparisonDividends
6.2%
Current Dividend Yield75%
Payout RatioCompany Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/18 10:33 |
End of Day Share Price | 2024/12/18 00:00 |
Earnings | 2024/06/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
RBC Bioscience Corporation is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|